Adnexus, a Bristol-Myers Squibb R&D Company, is leading the discovery and development of Adnectinsâ„¢, a novel, proprietary class of targeted biologics. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to fight diseases across a broad range of therapeutic areas. Their proprietary technology for engineering these versatile proteins creates an opportunity to rapidly generate highly differentiated medicines.
Adnexus, a Bristol-Myers Squibb R&D Company, is a leader in the discovery and development of Adnectins, a proprietary type of targeted biologic. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to help fight diseases across a broad range of therapeutic areas. Our proprietary technology for engineering these proteins creates an opportunity to rapidly generate compounds for study as potential treatment options for patients.
Targeted biologics are one of the most medically important and fastest growing areas in the biopharmaceutical industry. These drugs are specifically designed to attack targets of disease. Despite the success of the first generation targeted therapeutic products, such as antibodies, additional innovations are sought by the medical community to help meet unmet needs for improved safety, and efficacy. We believe the study of Adnectins can help to address these demands.
Adnectins are derived from human fibronectin, an abundant extracellular protein that binds naturally to a number of different proteins. We create Adnectins using our proprietary protein engineering system called PROfusion™. Our scientists can rapidly create PROfusion libraries of more than 10 trillion different Adnectins. We then screen these libraries to identify Adnectins with the desired drug properties against therapeutic targets of interest. PROfusion enables discovery productivity by minimizing the timeframe for identifying high-quality candidates.
In October 2007, Adnexus was acquired by Bristol-Myers Squibb Company. This acquisition has further accelerated our growth as an industry leader in the discovery and early development of proprietary targeted biologics. Together with Bristol-Myers Squibb, we are developing multiple Adnectin programs for use in the study of potential treatments in a broad range of disease types, including oncology, immunology, and cardiovascular disease.
Funding Rounds (3) - $55.5MUpdate
|Aug 4, 2016||Business Wire - Dicerna Reports Second Quarter 2016 Financial and Operational Results|
|Jun 15, 2016||Business Wire - Dicerna Appoints Martin Freed, M.D., to Board of Directors|
|May 20, 2016||PRNewswire UK All - Next-Generation Biologics Market 2016-2026|
|May 20, 2016||PRNewswire All - Next-Generation Biologics Market 2016-2026|
|Mar 30, 2016||Xconomy - With New Execs, Sanofi Backing, ImmuneXcite Begins Clinical Push|
|Jan 18, 2016||LifeSciVC | Recovering scientist turned early stage VC - Early Stage Biotech Financing: Fewer, Leaner, and Better?|
|Jan 18, 2016||LifeSciVC | Recovering scientist turned early stage VC - Virtues of Differing Biotech Worldviews|
|Jan 18, 2016||LifeSciVC | Recovering scientist turned early stage VC - The Biotech Venture Capital Math Problem|
100 Beaver Street
Waltham, MA 02453